Transcatheter aortic valve implant (TAVI) is gaining momentum in the treatment of severe, symptomatic aortic valve stenosis, and its indication is expanding to lower surgical risk individuals, who are generally younger and have a long life expectancy. Therefore, transcatheter bioprostheses durability appears of critical importance. Aim of the present study is to evaluate mid-term outcomes of TAVI in a high-volume single center cohort.
Transcatheter aortic bioprosthesis durability: A single center experience / Moroni, F., Ziviello, F., Federico, F., Di Stefano, D., Beneduce, A., Vella, C.S., Ancona, F., Ingallina, G., Ancona, M., Ferri, L.A., Russo, F., Bellini, B., Agricola, E., Chieffo, A., Montorfano, M.. - In: CARDIOVASCULAR REVASCULARIZATION MEDICINE. - ISSN 1553-8389. - (2022). [Epub ahead of print] [10.1016/j.carrev.2022.05.011]
Transcatheter aortic bioprosthesis durability: A single center experience
Moroni, Francesco;Agricola, Eustachio;Chieffo, Alaide;Montorfano, Matteo
2022-01-01
Abstract
Transcatheter aortic valve implant (TAVI) is gaining momentum in the treatment of severe, symptomatic aortic valve stenosis, and its indication is expanding to lower surgical risk individuals, who are generally younger and have a long life expectancy. Therefore, transcatheter bioprostheses durability appears of critical importance. Aim of the present study is to evaluate mid-term outcomes of TAVI in a high-volume single center cohort.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S155383892200241X-main.pdf
solo gestori archivio
Tipologia:
Submitted manuscript (manoscritto inviato all’editore)
Licenza:
Altra licenza OA
Dimensione
642.04 kB
Formato
Adobe PDF
|
642.04 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
